Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX) announced that President and CEO Masoud Toloue and CFO Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, at 4:30 p.m. EST in Boston, MA. They will engage in one-on-one and group meetings with institutional investors on the same day. A live webcast of the presentation will be available on Quanterix's Investor website, with replays accessible for 90 days. Quanterix specializes in ultrasensitive biomarker detection aimed at advancing research in various medical fields.

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue and Chief Financial Officer Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 17, 2022 at 4:30 p.m. EST in Boston, MA. Toloue will also host one-on-one and group meetings with institutional investors that day.

A live webcast of the conversation will be available on the Investors section of the Quanterix website at https://ir.quanterix.com/. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ^® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005997/en/

Media:

PAN Communications

Lauren Force

(610) 574-0565

pan.quanterix@pancomm.com



Investor Relations:

Amy Achorn

(978) 488-1854

ir@quanterix.com

Source: Quanterix Corporation

FAQ

When is Quanterix's presentation at the CG MedTech Forum?

Quanterix's presentation at the CG MedTech, Diagnostics and Digital Health & Services Forum is scheduled for November 17, 2022, at 4:30 p.m. EST.

Who will represent Quanterix at the conference?

Masoud Toloue, President and CEO, and Michael Doyle, CFO, will represent Quanterix at the conference.

Where can I watch the Quanterix presentation live?

The live webcast of Quanterix's presentation will be available on their Investor Relations website.

How long will the Quanterix webcast be available after the event?

The replay of the Quanterix webcast will be available for 90 days following the conference.

What does Quanterix specialize in?

Quanterix specializes in ultrasensitive biomarker detection that supports research in neurology, oncology, immunology, cardiology, and infectious diseases.